EGFR,HER2和HER3在胆管癌中的表达及预后价值

doi:10.11904/j.issn.1002-3070.2019.06.003

摘要/Abstract

摘要： 目的观察表皮生长因子受体(Epidermal growth factor receptor,EGFR)、表皮生长因子受体2(Human epidermal growth factor receptor 2,HER2)和表皮生长因子受体3(Human epidermal growth factor receptor 3,HER3)在胆管癌(Cholangiocarcinoma,CCA)组织中的表达情况,探讨其与CCA患者临床病理特征、总生存期和CCA细胞增殖的关系。方法收集2009年1月—2013年10月于我院手术的CCA患者50例,并同时收取癌旁组织作为对照。采用免疫组织化学方法及RT-PCR方法检测CCA及癌旁组织中EGFR、HER2和HER3表达情况。收集患者临床病理参数,分析EGFR、HER2和HER3表达与CCA临床病理参数之间的关系。绘制Kaplan-Meier生存曲线,采用Log-rank检验和Cox比例风险模型分析EGFR、HER2和HER3表达情况与50例CCA患者术后总生存期之间的关系。采用RNA干扰方法敲低CCA细胞株QBC939中EGFR、HER2和HER3表达,Western blot检测EGFR、HER2和HER3敲低效果,MTT方法检测EGFR、HER2和HER3对QBC939细胞增殖的影响。结果 CCA组织中可检测到EGFR、HER2和HER3的阳性表达。临床病理特征关系分析结果显示,HER2表达与CCA淋巴结转移相关(P＜0.05);而EGFR和HER3除与CCA淋巴结转移相关外,还与肿瘤分化程度相关(P＜0.05)。EGFR、HER2和HER3阳性患者术后总生存期明显低于阴性患者(P＜0.05)。敲低CCA QBC939细胞中EGFR、HER2和HER3表达后,QBC939细胞增殖能力显著降低(P＜0.05)。结论 CCA组织中EGFR、HER2和HER3表达与患者总生存期密切相关,机制可能与促进CCA细胞的增殖相关。

关键词: 表皮生长因子受体, 表皮生长因子受体2, 表皮生长因子受体3, CCA, 增殖

Abstract: Objective The aim of this study was to observe the expression of human epidermal growth factor receptor(EGFR),epidermal growth factor receptor 2(HER2)and epidermal growth factor receptor 3(HER3)in cholangiocarcinoma(CCA),and to explore the relationship between the expression of EGFR,HER2,HER3 and the clinicopathological features,overall survival time and proliferation of CCA patients.Methods Fifty patients with CCA who underwent surgery in our hospital from January 2009 to October 2013 were enrolled,and their adjacent tissues were also collected as controls.Immunohistochemistry and qRT-PCR were used to detect the expression of EGFR,HER2 and HER3 in CCA and adjacent tissues.The clinicopathological parameters of patients were collected and the relationship between EGFR,HER2,and HER3 expression and clinicopathological parameters of CCA was analyzed.Kaplan-Meier survival curves were plotted,and the relationship between the expression of EGFR,HER2,and HER3 and total postoperative survival of 50 patients with CCA was analyzed using the Log-rank test and Cox proportional hazard model.The expression of EGFR,HER2 and HER3 in CCA QBC939 cell line was knocked down by RNA interference assay.The knockdown effect of EGFR,HER2 and HER3 was detected by Western blot.The effect of EGFR,HER2 and HER3 on proliferation of QBC939 cells was determined by MTT assay.Results The positive expression of EGFR,HER2 and HER3 was determined in CCA tissues.The relationship analysis of clinicopathological characteristics showed that the HER2 expression was associated with CCA lymph node metastasis(P＜0.05).EGFR and HER3 was associated with CCA lymph node metastasis and correlated with cancer differentiation(P＜0.05).The overall survival of patients with EGFR,HER2 and HER3 positive was significantly lower than that of negative patients(P＜0.05).After knocking EGFR,HER2 and HER3 expression,the proliferation was significantly decreased in QBC939 cells(P＜0.05).Conclusion The expression of EGFR,HER2 and HER3 in CCA tissues is closely related to the overall survival of patients,and the mechanism may be related to the promotion of proliferation of CCA cells.

Key words: Epidermal growth factor receptor, Human epidermal growth factor receptor 2, Human epidermal growth factor receptor 3, Cholangiocarcinoma, Proliferation

中图分类号:

R735.8

詹琦, 周晟, 娄丽萍. EGFR,HER2和HER3在胆管癌中的表达及预后价值[J]. 实用肿瘤学杂志, 2019, 33(6): 491-496.

ZHAN Qi, ZHOU Sheng, LOU Liping. The expression and prognostic value of EGFR,HER2 and HER3 in cholangiocarcinoma[J]. Journal of Practical Oncology, 2019, 33(6): 491-496.

0
/ / 推荐

导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

链接本文: http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/10.11904/j.issn.1002-3070.2019.06.003

http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/Y2019/V33/I6/491

参考文献

1 Krasinskas AM.Cholangiocarcinoma[J].Surg Pathol Clin,2018,11(2):403-429.
2 Baheti AD,Tirumani SH,Rosenthal MH,et al.Diagnosis and management of intrahepatic cholangiocarcinoma:A comprehensive update for the radiologist[J].Clin Radiol,2014,69(12):463-470.
3 Yang X,Wang W,Wang C,et al.Characterization of EGFR family gene aberrations in cholangiocarcinoma[J].Oncol Rep,2014,32(2):700-708.
4 Kosriwong K,Menheniott TR,Giraud AS,et al.Trefoil factors:tumor progression markers and mitogens via EGFR/MAPK activation in cholangiocarcinoma[J].World J Gastroenterol,2011,17(12):1631-1641.
5 Xu L,Hausmann M,Dietmaier W,et al.Expression of growth factor receptors and targeting of EGFR in cholangiocarcinoma cell lines[J].BMC Cancer,2010,10:302.
6 Law LY.Dramatic response to trastuzumab and paclitaxel in a patient with human epidermal growth factor receptor 2-positive metastatic cholangiocarcinoma[J].J Clin Oncol,2012,30(27):271-273.
7 Nanda S.Cancer:A limited role for dual EGFR and HER2 inhibition in cholangiocarcinoma?[J].Nat Rev Gastroenterol Hepatol,2010,7(11):591.
8 Treekitkarnmongkol W,Suthiphongchai T.High expression of HER2 contributes to cholangiocarcinoma cell invasion and proliferation through AKT/p70S6K[J].World J Gastroenterol,2010,16(32):4047-4054.
9 Bieche I,Onody P,Tozlu S,et al.Prognostic value of ERBB family mRNA expression in breast carcinomas[J].Int J Cancer,2003,106(5):758-765.
10 Bae SY,La Choi Y,Kim S,et al.HER3 status by immunohistochemistry is correlated with poor prognosis in hormone receptor-negative breast cancer patients[J].Breast Cancer Res Treat,2013,139(3):741-750.
11 Singhai A,Wakefield DL,Bryant KL,et al.Spatially defined EGF receptor activation reveals an f-actin-dependent phospho-erk signaling complex[J].Biophys J,2014,107(11):2639-2651.
12 Duan H,Qu L,Shou C.Activation of EGFR-PI3K-AKT signaling is required for Mycoplasma hyorhinis-promoted gastric cancer cell migration[J].Cancer Cell Int,2014,14(1):135.
13 Fan QW,Cheng CK,Gustafson WC,et al.EGFR phosphorylates tumor-derived EGFRvIII driving STAT3/5 and progression in glioblastoma[J].Cancer Cell,2013,24(4):438-449.
14 Omenn GS,Guan Y,Menon R.A new class of protein cancer biomarker candidates:differentially expressed splice variants of HER2(HER2/neu)and ERBB1(EGFR)in breast cancer cell lines[J].J Proteomics,2014,107:103-112.
15 Duan H,Qu L,Shou C.Activation of EGFR-PI3K-AKT signaling is required for Mycoplasma hyorhinis-promoted gastric cancer cell migration[J].Cancer Cell Int,2014,14(1):135.
16 Demir L,Yigit S,Sadullahoglu C,et al.Hormone receptor,HER2/NEU and EGFR expression in ovarian carcinoma - is here a prognostic phenotype?[J].Asian Pac J Cancer Prev,2014,15(22):9739-9745.
17 Hudson SV,Huang JS,Yin W,et al.Targeted noninvasive imaging of EGFR-expressing orthotopic pancreatic cancer using multispectral optoacoustic tomography[J].Cancer Res,2014,74(21):6271-6279.
18 Araki K,,Miyoshi Y.Mechanism of resistance to endocrine therapy in breast cancer:the important role of PI3K/Akt/mTOR in estrogen receptor-positive,HER2-negative breast cancer[J].Breast Cancer,2018,25(4):392-401.
19 Hedner C,Borg D,Nodin B,et al.Expression and prognostic significance of human epidermal growth factor 1,2 and 3 in oesophageal and gastric adenocarcinomas preneoadjuvant and postneoadjuvant treatment[J].J Clin Patho,2018,71(5):451-462.

[1]	黄梨, 龙佑梅, 付义霞, 夏良斌. 紫檀芪对卵巢癌SKOV3细胞凋亡和糖酵解的影响及机制研究[J]. 实用肿瘤学杂志, 2019, 33(6): 502-507.
[2]	陈光浩, 方靖萱, 彭素娟, 严炜薇, 王福海, 陈承哲, 陈泗川, 潘建基, 邱素芳. PNCK对鼻咽癌细胞增殖和凋亡作用的研究[J]. 实用肿瘤学杂志, 2019, 33(5): 397-401.
[3]	申利, 魏军成. miRNA-409-3p表达水平对宫颈癌细胞增殖及顺铂化疗敏感性的影响[J]. 实用肿瘤学杂志, 2019, 33(4): 300-304.
[4]	李景, 吴华珍, 刘继琐. miR-362靶向Six1抑制宫颈癌细胞增殖、迁移的作用机制研究[J]. 实用肿瘤学杂志, 2019, 33(4): 310-316.
[5]	闫若东, 任山, 隋文印, 朴仁京. TMEM45A在肾透明细胞癌中的表达及作用机制研究[J]. 实用肿瘤学杂志, 2019, 33(4): 317-322.
[6]	刘志强,褚艳杰,刘静,王彦博. m白术内酯Ⅰ通过TLR4/MyD88通路调控肺癌A549细胞增殖侵袭的研究[J]. 实用肿瘤学杂志, 2019, 33(3): 228-232.
[7]	白晓斌, 霍龙伟, 谢万福, 徐高峰, 王茂德. Chk1在胶质母细胞瘤中的表达及其与肿瘤生物学行为和预后生存的关联性[J]. 实用肿瘤学杂志, 2019, 33(2): 122-127.
[8]	袁桂霞, 李岩, 冯婉琪, 夏小娟, 李旭. 抑癌基因DKK2抑制儿童肾母细胞瘤细胞增殖的机制研究[J]. 实用肿瘤学杂志, 2019, 33(1): 14-20.
[9]	卞秀森, 李光, 关欣宇, 张伊, 狄畅, 马璨. UHRF1通过调控细胞自噬抑制肺腺癌细胞增殖的分子机制研究[J]. 实用肿瘤学杂志, 2018, 32(6): 498-502.
[10]	刘娟综述, 张澍田审校. 细胞周期蛋白依赖性激酶抑制因子3在肿瘤中的研究进展[J]. 实用肿瘤学杂志, 2018, 32(6): 575-578.
[11]	李万祯, 殷俊, 李萍, 林晓辉, 张国前, 张书旭. iR-17在非小细胞肺癌放射抗拒细胞中的表达及作用研究[J]. 实用肿瘤学杂志, 2018, 32(5): 391-397.
[12]	陈鳞, 王恩湘, 刘群友, 钟鹰, 周国良, 赵喜雁. CDX2基因通过NF-κB信号通路抑制结肠癌细胞增殖[J]. 实用肿瘤学杂志, 2018, 32(5): 398-403.
[13]	陈兆红, 何迎盈, 张友才, 鲁丁瑜. 过表达SOX7对胆囊癌GBC-SD细胞增殖生物学特性的影响及其机制研究[J]. 实用肿瘤学杂志, 2018, 32(4): 293-297.
[14]	李文辉, 吕博文, 钱钧, 苏丽菊, 杨桐树, 钱景荣, 王杰. MicroRNA-150对上皮性卵巢癌细胞增殖、凋亡和侵袭转移能力的影响[J]. 实用肿瘤学杂志, 2018, 32(3): 208-213.
[15]	闫石, 霍明鸣, 庞慧, 李焱, 蔡莉. p53对绝经后HR阳性、HER-2阳性术后乳腺癌患者内分泌药物疗效的预测价值[J]. 实用肿瘤学杂志, 2018, 32(3): 234-213.